PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
LXRX vs. GERN
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between LXRX and GERN is 0.36, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.4

Performance

LXRX vs. GERN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Lexicon Pharmaceuticals, Inc. (LXRX) and Geron Corporation (GERN). The values are adjusted to include any dividend payments, if applicable.

-60.00%-40.00%-20.00%0.00%20.00%40.00%AugustSeptemberOctoberNovemberDecember2025
-41.80%
-25.81%
LXRX
GERN

Key characteristics

Sharpe Ratio

LXRX:

-0.36

GERN:

0.63

Sortino Ratio

LXRX:

0.10

GERN:

2.47

Omega Ratio

LXRX:

1.01

GERN:

1.28

Calmar Ratio

LXRX:

-0.37

GERN:

0.71

Martin Ratio

LXRX:

-0.72

GERN:

4.66

Ulcer Index

LXRX:

51.50%

GERN:

14.83%

Daily Std Dev

LXRX:

102.49%

GERN:

110.22%

Max Drawdown

LXRX:

-99.80%

GERN:

-98.65%

Current Drawdown

LXRX:

-99.72%

GERN:

-94.85%

Fundamentals

Market Cap

LXRX:

$266.96M

GERN:

$2.14B

EPS

LXRX:

-$0.74

GERN:

-$0.32

PEG Ratio

LXRX:

-0.14

GERN:

-2.38

Total Revenue (TTM)

LXRX:

$4.53M

GERN:

$29.46M

Gross Profit (TTM)

LXRX:

$4.12M

GERN:

$28.67M

EBITDA (TTM)

LXRX:

-$155.66M

GERN:

-$138.52M

Returns By Period

In the year-to-date period, LXRX achieves a 25.92% return, which is significantly higher than GERN's -3.95% return. Over the past 10 years, LXRX has underperformed GERN with an annualized return of -17.77%, while GERN has yielded a comparatively higher 0.77% annualized return.


LXRX

YTD

25.92%

1M

31.88%

6M

-41.88%

1Y

-39.22%

5Y*

-25.71%

10Y*

-17.77%

GERN

YTD

-3.95%

1M

-13.49%

6M

-25.76%

1Y

58.14%

5Y*

20.01%

10Y*

0.77%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

LXRX vs. GERN — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

LXRX
The Risk-Adjusted Performance Rank of LXRX is 3131
Overall Rank
The Sharpe Ratio Rank of LXRX is 2828
Sharpe Ratio Rank
The Sortino Ratio Rank of LXRX is 3636
Sortino Ratio Rank
The Omega Ratio Rank of LXRX is 3636
Omega Ratio Rank
The Calmar Ratio Rank of LXRX is 2525
Calmar Ratio Rank
The Martin Ratio Rank of LXRX is 3232
Martin Ratio Rank

GERN
The Risk-Adjusted Performance Rank of GERN is 7979
Overall Rank
The Sharpe Ratio Rank of GERN is 6969
Sharpe Ratio Rank
The Sortino Ratio Rank of GERN is 8787
Sortino Ratio Rank
The Omega Ratio Rank of GERN is 8383
Omega Ratio Rank
The Calmar Ratio Rank of GERN is 7474
Calmar Ratio Rank
The Martin Ratio Rank of GERN is 8181
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

LXRX vs. GERN - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Lexicon Pharmaceuticals, Inc. (LXRX) and Geron Corporation (GERN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for LXRX, currently valued at -0.36, compared to the broader market-4.00-2.000.002.00-0.360.63
The chart of Sortino ratio for LXRX, currently valued at 0.10, compared to the broader market-4.00-2.000.002.004.000.102.47
The chart of Omega ratio for LXRX, currently valued at 1.01, compared to the broader market0.501.001.502.001.011.28
The chart of Calmar ratio for LXRX, currently valued at -0.37, compared to the broader market0.002.004.006.00-0.370.73
The chart of Martin ratio for LXRX, currently valued at -0.72, compared to the broader market-10.000.0010.0020.00-0.724.66
LXRX
GERN

The current LXRX Sharpe Ratio is -0.36, which is lower than the GERN Sharpe Ratio of 0.63. The chart below compares the historical Sharpe Ratios of LXRX and GERN, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-0.500.000.501.00AugustSeptemberOctoberNovemberDecember2025
-0.36
0.63
LXRX
GERN

Dividends

LXRX vs. GERN - Dividend Comparison

Neither LXRX nor GERN has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

LXRX vs. GERN - Drawdown Comparison

The maximum LXRX drawdown since its inception was -99.80%, roughly equal to the maximum GERN drawdown of -98.65%. Use the drawdown chart below to compare losses from any high point for LXRX and GERN. For additional features, visit the drawdowns tool.


-100.00%-95.00%-90.00%-85.00%AugustSeptemberOctoberNovemberDecember2025
-99.72%
-89.72%
LXRX
GERN

Volatility

LXRX vs. GERN - Volatility Comparison

Lexicon Pharmaceuticals, Inc. (LXRX) has a higher volatility of 36.12% compared to Geron Corporation (GERN) at 11.13%. This indicates that LXRX's price experiences larger fluctuations and is considered to be riskier than GERN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%20.00%30.00%40.00%50.00%AugustSeptemberOctoberNovemberDecember2025
36.12%
11.13%
LXRX
GERN

Financials

LXRX vs. GERN - Financials Comparison

This section allows you to compare key financial metrics between Lexicon Pharmaceuticals, Inc. and Geron Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab